Cargando…
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
Purpose Pertuzumab and T-DM1 are two efficient anti-HER2 treatments for patients with HER2-positive advanced breast cancer. While pertuzumab is usually given in first-line treatment and T-DM1 in second-line treatment, standard therapy options seem to be exhausted up to now after the treatment of pat...
Autores principales: | Laakmann, Elena, Emons, Julius, Taran, Florin-Andrei, Janni, Wolfgang, Uhrig, Sabrina, Overkamp, Friedrich, Kolberg, Hans-Christian, Hadji, Peyman, Tesch, Hans, Häberle, Lothar, Ettl, Johannes, Lüftner, Diana, Wallwiener, Markus, Schulmeyer, Carla, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Wimberger, Pauline, Hielscher, Carsten, Kurbacher, Christian, Wuerstlein, Rachel, Thomssen, Christoph, Untch, Michael, Volz, Bernhard, Fasching, Peter A., Fehm, Tanja N., Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, Lux, Michael P., Hartkopf, Andreas D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647719/ https://www.ncbi.nlm.nih.gov/pubmed/33173241 http://dx.doi.org/10.1055/a-1286-2917 |
Ejemplares similares
-
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020) -
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020) -
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018) -
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
por: Schneeweiss, Andreas, et al.
Publicado: (2020) -
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT
por: Engler, Tobias, et al.
Publicado: (2022)